This week, a study finds that injectable cabotegravir, an investigational integrase inhibitor, is well tolerated and shows promise as pre-exposure prophylaxis (PrEP).
This Week in HIV Research: Effect of Viral Load Perception on Sex, and HIV Prevention Options Needed in U.S. Prisons
This week, a study finds that viral load perception may change sexual behaviors among HIV-positive men who have sex with men.
This week, a study finds a new key step in how HIV binds to CD4 cells, which could lead to the development of new HIV drugs.
This Week in HIV Research: Early Treatment With Broadly Neutralizing Antibodies Suppresses SHIV in Monkeys
This week, a study finds that administering two broadly neutralizing antibodies very early on during infection helped monkeys achieve long-term viral suppression of simian HIV (SHIV).
This Week in HIV Research: Long-Term Nonprogressors Have Greater Thymic Function; and HCV Reinfection Rates Examined
This week, a study finds that thymic function, which is associated with higher CD4 counts in people with HIV, is greater in long-term nonprogressors.
This week, a study finds that a treatment regimen containing lamivudine may work as maintenance therapy for those already virally suppressed.
During the last 18 years, both the amount of prescription opioids and the number of deaths attributed to these drugs has quadrupled in the U.S., Glenn J. Treisman, M.D., Ph.D., said in a recent webinar.
This week, a study finds that stable housing can improve CD4 counts and viral load suppression rates in people with HIV.
This Week in HIV Research: Continuous Treatment Adherence Increases; and Programs Needed for Quitting Smoking
This week, a study finds that continuous HIV treatment adherence, without a 90-day gap, has increased between 2001 and 2010, and is now longer than adherence to medication for some other chronic diseases.
This week, a special issue of The Journal of Infectious Diseases highlights HIV cure research. And a study compares TAF and TDF in triple-drug regimens.